Current Report Filing (8-k)
October 30 2018 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 24, 2018
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36500
|
|
94-3103561
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address
of principal executive offices)
(510)
293-8800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 1.02.
|
Termination of a Material Definitive Agreement.
|
On October 24, 2018, CymaBay Therapeutics, Inc. (CymaBay) received notice from Kowa Pharmaceuticals America, Inc.
(Kowa) that Kowa was terminating the Exclusive License Agreement dated December 30, 2016, between CymaBay and Kowa (the License Agreement). In the License Agreement CymaBay granted to Kowa an exclusive license to certain
patent rights and technology related to arhalofenate, CymaBays product candidate for the treatment of gout. The license covered the development and commercialization of the licensed technology in the United States (including all possessions
and territories). The termination will be effective on January 22, 2019. There are no termination or other payments due to CymaBay as a result of the termination.
Arhalofenate is a Phase 3 ready, dual-acting anti-inflammatory and uricosuric drug candidate that had been in development as a combination
with febuxostat for patients with gout. CymaBay does not have any current plans to initiate Phase 3 development of arhalofenate in gout as a result of regaining the U.S. rights to the program.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
CymaBay Therapeutics, Inc.
|
|
|
By:
|
|
/s/ Paul Quinlan
|
Name:
|
|
Paul Quinlan
|
Title:
|
|
General Counsel
|
Dated: October 30, 2018
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Apr 2023 to Apr 2024